On very short review it just seems to be a full-body MRI, which has the benefit of negligible radiation dose, but isn’t the best medium for detecting some cancers and metastasis (eg lung, lymph nodes). I’m also guessing it’s not targeted enough in dosimetry and contrast etc. for some specific body parts which are most concerning for CRC metastases (eg liver). Without claiming to be an expert by any stretch, I’d be suggesting that the best surveillance protocol is one developed by your oncologist/surgeon using evidence-based guidelines, not one marketed by a private company. My surveillance routine has involved a combination of CT and PET-CT, interspersed with dedicated liver MRIs, to get the best overall coverage and sensitivity.
Might be ok if you didn’t have cancer and just wanted some peace-of-mind, but for a post-diagnosis surveillance regime where getting the right early detection can truly mean life-or-death, I wouldn’t personally be taking any chances!
2018 Dx RC, 12cm high
Mod diff, EMVI+ LVI+. 4 liver mets
pT3N1aM1a Stage IVa. MSS NRAS G13R
CEA: Nov-18= 14, Mar-19= 2.4, Aug-19 <2.0, Mar-20=2.2, May-20=1.9, Jun-20=2.1, Sep-20: 2.1, Dec-20: 2.3, Mar-21=2.5, Jul-21=3.1
11/18 FOLFOX x6
3/19 Liver resection
5/19 25x pelvic radiation; complete met. response
07/19 ULAR w ileo, 1/27 LN+
08/19 Found liver spot
08/19 FOLFOX x1, FOLFOXIRI x1, FOLFIRI x5
12/19 Liver resection
02/20 Ileo reversed
03/20 NED (CT/PET/MRI/scope) - latest scans Jul-21